IXICO plc (PHYOF)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -1.17 Million USD | -239.23% |
| 2022 | 1.03 Million USD | -49.34% |
| 2021 | 2.03 Million USD | 113.97% |
| 2020 | 952 Thousand USD | 120.37% |
| 2019 | 432 Thousand USD | 149.59% |
| 2018 | -871.1 Thousand GBP | 57.76% |
| 2017 | -2.06 Million GBP | 25.08% |
| 2016 | -2.75 Million GBP | -130.53% |
| 2015 | -1.19 Million GBP | 57.18% |
| 2014 | -2.78 Million GBP | 41.5% |
| 2013 | -4.76 Million GBP | 38.62% |
| 2012 | -7.76 Million GBP | -1.41% |
| 2011 | -7.65 Million GBP | -101.43% |
| 2010 | -3.8 Million GBP | 2.79% |
| 2009 | -3.91 Million GBP | -71.91% |
| 2008 | -2.27 Million GBP | 0.0% |
| 2007 | - GBP | 100.0% |
| 2006 | -5.63 Million GBP | -69.49% |
| 2005 | -3.32 Million GBP | 46.56% |
| 2004 | -6.22 Million GBP | -17.41% |
| 2003 | -5.3 Million GBP | -61.48% |
| 2002 | -3.28 Million GBP | -23.78% |
| 2001 | -2.65 Million GBP | -21.53% |
| 2000 | -2.18 Million GBP | 32.23% |
| 1999 | -3.22 Million GBP | 11.36% |
| 1998 | -3.63 Million GBP | -18.56% |
| 1997 | -3.06 Million GBP | -442.48% |
| 1996 | -565 Thousand GBP | -398.94% |
| 1995 | 189 Thousand GBP | 108.6% |
| 1994 | -2.19 Million GBP | -205.14% |
| 1993 | -720 Thousand GBP | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -1.78 Million USD | 0.0% |
| 2023 FY | -1.43 Million USD | -239.23% |
| 2023 Q2 | -894.14 Thousand USD | 0.0% |
| 2023 Q4 | -552.52 Thousand USD | 0.0% |
| 2022 Q4 | 910.65 Thousand USD | 0.0% |
| 2022 Q2 | 283.67 Thousand USD | 0.0% |
| 2022 FY | 1.03 Million USD | -49.34% |
| 2021 Q2 | 1.16 Million USD | 0.0% |
| 2021 Q4 | 987.49 Thousand USD | 0.0% |
| 2021 FY | 2.03 Million USD | 113.97% |
| 2020 Q4 | 616.66 Thousand USD | 0.0% |
| 2020 FY | 952 Thousand USD | 120.37% |
| 2020 Q2 | 588.97 Thousand USD | 0.0% |
| 2019 FY | 432 Thousand USD | 149.59% |
| 2019 Q4 | 267.4 Thousand USD | 0.0% |
| 2018 FY | -871.1 Thousand GBP | 57.76% |
| 2017 FY | -2.06 Million GBP | 25.08% |
| 2016 FY | -2.75 Million GBP | -130.53% |
| 2015 FY | -1.19 Million GBP | 57.18% |
| 2014 FY | -2.78 Million GBP | 41.5% |
| 2013 FY | -4.76 Million GBP | 38.62% |
| 2012 FY | -7.76 Million GBP | -1.41% |
| 2011 FY | -7.65 Million GBP | -101.43% |
| 2010 FY | -3.8 Million GBP | 2.79% |
| 2009 FY | -3.91 Million GBP | -71.91% |
| 2008 FY | -2.27 Million GBP | 0.0% |
| 2007 FY | - GBP | 100.0% |
| 2006 FY | -5.63 Million GBP | -69.49% |
| 2005 FY | -3.32 Million GBP | 46.56% |
| 2004 FY | -6.22 Million GBP | -17.41% |
| 2003 FY | -5.3 Million GBP | -61.48% |
| 2002 FY | -3.28 Million GBP | -23.78% |
| 2001 FY | -2.65 Million GBP | -21.53% |
| 2000 FY | -2.18 Million GBP | 32.23% |
| 1999 FY | -3.22 Million GBP | 11.36% |
| 1998 FY | -3.63 Million GBP | -18.56% |
| 1997 FY | -3.06 Million GBP | -442.48% |
| 1996 FY | -565 Thousand GBP | -398.94% |
| 1995 FY | 189 Thousand GBP | 108.6% |
| 1994 FY | -2.19 Million GBP | -205.14% |
| 1993 FY | -720 Thousand GBP | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 52.97 Million USD | 102.224% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -86.272% |
| Nascent Biotech, Inc. | -2.08 Million USD | 43.574% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -183.528% |
| Qrons Inc. | -789.34 Thousand USD | -49.237% |
| Rebus Holdings, Inc. | -1.02 Million USD | -15.49% |
| Skye Bioscience, Inc. | -37.64 Million USD | 96.871% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 101.809% |
| Adynxx, Inc. | - USD | Infinity% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 11.789% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 98.118% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 92.578% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 83.13% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 98.429% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 82.087% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | -330.867% |
| SQZ Biotechnologies Company | -79.46 Million USD | 98.518% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 59.272% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 35.293% |
| Mesoblast Limited | -87.95 Million USD | 98.661% |
| Marizyme, Inc. | -65.34 Million USD | 98.197% |
| Genus plc | 7.9 Million USD | 114.911% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 89.184% |
| Pharming Group N.V. | -10.54 Million USD | 88.832% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 45.71% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 68.25% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 86.68% |
| ContraFect Corporation | -65.15 Million USD | 98.192% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 75.891% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 31.807% |
| IMV Inc. | -36.48 Million USD | 96.771% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 85.384% |
| MultiCell Technologies, Inc. | -380.07 USD | -309842.905% |
| ONE Bio Corp. | 8.67 Million USD | 113.577% |
| Accustem Sciences Inc. | -3.74 Million USD | 68.557% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 97.721% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 7.034% |
| Q BioMed Inc. | -2.05 Million USD | 42.595% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 68.444% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 50.522% |
| Biomind Labs Inc. | -1.21 Million USD | 2.991% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 98.028% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 62.022% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 85.094% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 39.566% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -7765.919% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 79.75% |
| GB Sciences, Inc. | -1.36 Million USD | 13.489% |
| Alpha Cognition Inc. | -13.77 Million USD | 91.447% |
| HST Global, Inc. | -146.21 Thousand USD | -705.69% |
| CSL Limited | 2.64 Billion USD | 100.045% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 32.869% |
| Halberd Corporation | -79.67 Thousand USD | -1378.488% |
| Enzolytics Inc. | -2.17 Million USD | 45.885% |
| Agentix Corp. | -1.37 Million USD | 14.278% |
| Resverlogix Corp. | -3.61 Million USD | 67.368% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 62.856% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.601% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 1302.041% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 117.012% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 70.35% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 61.072% |
| AVAX Technologies, Inc. | -6.41 Million USD | 81.633% |
| Zenith Capital Corp. | -10.59 Million USD | 88.883% |
| Genscript Biotech Corporation | -95.47 Million USD | 98.766% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -4968.411% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 71.587% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -1849.021% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 41.25% |
| Kadimastem Ltd | -3.3 Million USD | 64.383% |
| Helix BioMedix, Inc. | -1.05 Million USD | -11.547% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 69.154% |
| BioStem Technologies, Inc. | -8.48 Million USD | 86.113% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | -166.897% |
| LadRx Corporation | 400.44 Thousand USD | 394.174% |
| Cell Source, Inc. | -5.32 Million USD | 77.862% |
| Regen BioPharma, Inc. | 1.02 Million USD | 215.094% |
| Regen BioPharma, Inc. | 1.02 Million USD | 215.094% |
| NovAccess Global Inc. | -4.76 Million USD | 75.3% |
| Affymax, Inc. | -14.42 Million USD | 91.833% |
| Itoco Inc. | -1.86 Million USD | 36.971% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 73.484% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 29.419% |
| Mobile Lads Corp. | -2.26 Million USD | 47.952% |
| CytoDyn Inc. | -49.84 Million USD | 97.636% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -1390.517% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | -416.379% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | -25.116% |
| SYBLEU INC | -180.3 Thousand USD | -553.341% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 26.956% |
| International Stem Cell Corporation | -131 Thousand USD | -799.237% |
| Bioxytran, Inc. | -4.28 Million USD | 72.477% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -2070.548% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 53.443% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 97.55% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 44.276% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | -50.854% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 62.816% |
| Neutra Corp. | -233.46 Thousand USD | -404.572% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 94.194% |
| PureTech Health plc | -65.69 Million USD | 98.207% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 94.461% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 88.133% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 97.938% |
| CSL Limited | 2.64 Billion USD | 100.045% |
| Cellectis S.A. | -103.17 Million USD | 98.858% |